Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia
Dec 1, 2020, 00:00 AM
10.1016/j.jval.2020.10.007
https://www.valueinhealthjournal.com/article/S1098-3015(20)34450-8/fulltext
Section Title :
CORRECTIONS
Section Order :
1671
First Page :
1671
Value Health. 2020;23(10):1292-1299.
Portions of the Article and Author Information section (namely the author contributions, conflict of interest disclosures, funding/support, role of funder, and acknowledgement statements) that were published with this paper were for a different article. This article appears correctly online.
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)34450-8&doi=10.1016/j.jval.2020.10.007
HEOR Topics :
- Clinical Outcomes
- Clinical Outcomes Assessment
- Cost-comparison, Effectiveness, Utility, Benefit Analysis
- Economic Evaluation
- Health Service Delivery & Process of Care
- Oncology
- Specific Diseases & Conditions
- Treatment Patterns and Guidelines